Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

September 20, 2017

Study Completion Date

September 20, 2017

Conditions
Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia
Interventions
DRUG

Astarabine (BST-236)

"Cohort # Astarabine Dose Number of Patients~1. 0.5 gr/m2 (0.3 age\>50) 3~2. 1.5 gr/m2(0.8age\>50) 3~3. 3.0 gr/m2(1.5 age\>50) 3~4. 4.5 gr/m2(2.3 age\>50) 6~5. 4.5 gr/m2 (no age limit) 3 up to 6~6. 6 gr/m2 (no age limit) 3 up to 6~Total number of patients: up to 24"

Trial Locations (2)

4655202

Rambam medical center hematology department, Haifa

Unknown

Tel Aviv Sourasky Medical Center, Tel Aviv

All Listed Sponsors
lead

BioSight Ltd.

INDUSTRY

NCT02544438 - Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter